ClinicalTrials.gg
RecruitingNCT05412927Updated Sep 30, 2025

AngelMed Guardian® System PMA Post Approval Study

An observational study in Acute Coronary Syndrome, sponsored by Angel Medical Systems. Recruiting at 18 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Angel Medical Systems · Observational

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Planned enrollment
39th of 79
500 · median 500
Started
2022
with 7 others
Observational
79 of 265
4 open now
Primary completion
2026-12
later than 9 of 20 live
Registered
243rd of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 39th largest by planned enrollment of the 79 observational ones that give a count, is one of 8 that started in 2022, is one of 79 observational ones, reaches primary completion later than 9 of the 20 other live ones, and was the 243rd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care.

Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.

Read the detailed description

The purpose of this prospective, non-randomized, single arm, event-based, multicenter trial is to assess: (1) the diagnostic accuracy of the device, (2) the compliance of the prescribing physician, (3) the experience of the implanting physician, (4) the experience of the emergency department physician and (5) the patient compliance for "Emergency" and "See Doctor" alerts. The adequacy of the training program for the prescribing physician, implanting physician, emergency department physician, and patients will be assessed.

A minimum of 500 patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events. These ACS events will contribute to the Positive Predictive Value (PPV) and false positive rate (FPR) endpoints of the study. The PAS will be completed once the 314 ACS events have been collected and adjudicated.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients who have had prior ACS events and who remain at high risk for recurrent ACS events. Patients will be identified by implanting physicians using standard of care requirements for elective commercial implants based on the appropriate labeling and indications for use of the AngelMed Guardian System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subject has at least one of the following conditions:

    1. Diabetes (Type I or Type II)
    2. Compromised renal function (Cr > 1.2 mg/dl or less than 50)
    3. TIMI Risk Score of at least 3

      2. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation.

      3. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure.

      4. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI.

      5. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:

    <!-- -->

    1. or amenorrhoeic during the past year
    2. Surgical sterilization
    3. Use of effective method

Exclusion criteria

Exclusion Criteria:

  • 1. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc.

    2. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location.

    3. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion.

    4. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest.

    5. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB.

    7. Subject has left ventricular hypertrophy evidenced by criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line.

    9. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years.

    10. There is evidence of unresolved infection (fever > 38o C and/or leukocytosis > 15,000).

    11. Subject has history of bleeding disorders or severe coagulopathy ( \< 100,000 plts/ml; or PT > 1.3 x reference range).

    12. Subject has had a hemorrhagic stroke or (TIA) in the past 6 months.

    13. Subject has a potentially fatal disease, such as cancer or congestive heart failure, associated with limitation of , which may lead to inadequate compliance to the protocol or confusing data interpretation.

    14. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures.

    15. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor.

    16. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is for at least 6 months.

    18. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Patients who have had prior ACS events.

    Patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be implanted with PMA P150009 AngelMed Guardian® System and enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events.

    Device: PMA P150009 AngelMed Guardian® System

Interventions

  • DevicePMA P150009 AngelMed Guardian® System

    The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention.

06

What researchers measure

Primary outcomes

  1. Efficacy (PPV and FPR)

    This study is a post approval study aiming to gather data from FDA approved and standard of care implants using the proprietary medical device created by Angel Medical Systems, The Guardian. The study is collecting specific information from the subjects, devices and index procedure to demonstrate non-inferior performance of a now FDA approved product in a commercial setting. The diagnostic accuracy of the device will be assessed by comparing the Positive Predictive Value (PPV) and the False Positive Rate (FPR) results in the PAS to the results for the same endpoints in the ALARMS-ON group in the PMA-Amendment (i.e. including patients who both had the device implanted and alarms turned on). The hypotheses will be assessed with performance goals for both PPV and FPR.

    Time frame: The PAS is a 3 year, event based study, looking to accumulate 314 ACS events. Patients will be seen for an in-office initial programming visit 7-14 days following implant and every 6 months thereafter until study exit or study completion.

Secondary outcomes

  1. Adequacy of Training Programs for Study Team and Patients

    Instances where the device is prescribed/implanted for patients that don't meet proper labeling criteria. Instances of system revisions, any system problem that requires invasive corrective procedures to resolve, required within 6mo. of implant. Instances of "Emergency" alarm non-compliance, failure to report to the ER within 72 hours of the alarm. Instances of "See Doctor" noncompliance, defined as failure to present to doctor within 2 weeks of alarm or reporting to ER instead of to doctor in response to alarm. Instances of patient non-success to reconfirm ability to distinguish between "Emergency" and "See Doctor," defined by being able to report the proper actions to take for each and what to do when only symptoms occur in the absence of an alarm. Instances of percutaneous intervention without at least one positive standard of care test reported on a site-based and visit-based basis.

    Time frame: The PAS is a 3 year, event based study, looking to accumulate 314 ACS events. Patients will be seen for an in-office initial programming visit 7-14 days following implant and every 6 months thereafter until study exit or study completion.

07

Study locations

12 of 18 sites recruiting
  • Phoenix Heart
    Glendale, Arizona 85306, United States
    Recruiting
  • Arizona Heart & Vascular Clinic
    Glendale, Arizona 85308, United States
    Recruiting
  • Southwest Cardiovascular Associates
    Mesa, Arizona 85208, United States
    Active, not recruiting

    Not enrolling at this site.

  • East Los Angeles Cardiology
    Los Angeles, California 90033, United States
    Recruiting
    • Prash Jayaraj, MD · Contactdrjraj@yahoo.com · 323-578-0078
    • Suresh Rao, MD · Principal investigator
    • Prash Jayaraj, MD · Sub investigator
  • Orange County Heart and Research Institute
    Orange, California 92868, United States
    Active, not recruiting

    Not enrolling at this site.

  • Clermont Ambulatory Surgical Center
    Clermont, Florida 34711, United States
    Recruiting
    • Saif Memon · Contactsaifoomemon@gmail.com · 407-965-9848
    • Usman Siddiqui, MD · Principal investigator
  • Daytona Heart Group
    Daytona Beach, Florida 32114, United States
    Recruiting
  • Florida Heart Rhythm Specialists
    Fort Lauderdale, Florida 33308, United States
    Recruiting
    • Carlos Guadamas · Contactcarlos.guadamas@flahrs.com · 954-678-9531
    • David Kenigsberg, MD · Principal investigator
    • Ahmed Osman, MD · Sub investigator
    • Ben Melnychuk, MD · Sub investigator
  • Institute for Cardiovascular Research Studies, Inc.
    Miami, Florida 33176, United States
    Recruiting
  • LEJ Medical, LLC
    New Smyrna Beach, Florida 32168, United States
    Suspended

    Not enrolling at this site.

  • Northside Hospital Cardiovascular Institute
    Atlanta, Georgia 30342, United States
    Recruiting
    • Tamara Wakhisi, CCRP · Contacttamara.wakhisi@northside.com · 404-236-8322
    • Katie Moore · Contactkatie.moore@northside.com · 404-236-8320
    • Cindy Grines, MD · Principal investigator
    • Alok Gambhir, MD · Sub investigator
    • Joshua Lovelock, MD · Sub investigator
    • David Wilson, MD · Sub investigator
  • Cardiovascular Associate Research
    Covington, Louisiana 70433, United States
    Active, not recruiting

    Not enrolling at this site.

  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
    Recruiting
    • Lisa Bica · Contactlbica@theheartclinics.com · 586-943-8867
    • Karla Gorio, PA · Principal investigator
    • Ghiath Mikdadi, MD · Sub investigator
  • North Shore Heart and Vascular
    Mandeville, Louisiana 70448, United States
    Active, not recruiting

    Not enrolling at this site.

  • Corewell Health
    Grand Rapids, Michigan 49503, United States
    Active, not recruiting

    Not enrolling at this site.

  • South Oklahoma Heart Research
    Oklahoma City, Oklahoma 73135, United States
    Recruiting
    • Julie White, BS · Contactjuliewhite@okheart.com · 405-628-6865
    • Asim Chohan, MD · Principal investigator
    • Naeem Tahirkheli, MD · Sub investigator
    • Marc Weitzel, MD · Sub investigator
  • Texan Cardiovascular Institute
    El Paso, Texas 79915, United States
    Recruiting
  • Medical City Hospital Forth Worth
    Fort Worth, Texas 76104, United States
    Recruiting
    • Sarma Bhagawathy, MD · Contactbhagawathy.sarma@hcahealthcare.com · 817-201-7419
    • Amir Malik, MD · Principal investigator
    • Farhan Ali, MD · Sub investigator
    • Karan Gupta, MD · Sub investigator
    • Seyed Khalafi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The study doctor will collect your personal and medical information. For example: Past and present medical records Research records Records about phone calls made as part of this research Records about your study visits Your information may be given to: The U.S. Food and Drug Administration (FDA), Department of Health and Human Services (DHHS) agencies, Governmental agencies in other countries, Governmental agencies to whom certain diseases (reportable diseases) must be reported Central IRB Why will this information be used and/or given to others? to do the research, to study the results, and to see if the research was done right.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The investigator is responsible for the preparation (review and signature) and/or retention of the records below. The following records are subject to inspection and must be retained for a period of two years after the date on which the study is terminated or completed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 34 industry-sponsored observational studies under Acute Coronary Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 51 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 9, 2022
StartActual
Sep 7, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05412927
Lead sponsor
Angel Medical Systems
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Sep 7, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 30, 2025

Study contacts

Jacqueline Finley, BS
Contact
jfinley@avertix.com
732.542.5551 ext. 106
Sasha John, PhD
Contact
sjohn@avertix.com
6466444661
David Keenan
study director · Angel Medical Systems Inc.
Sasha John, PhD
study director · Angel Medical Systems Inc.
Haroon Faraz, MD
principal investigator · Hackensack-Meridian Health Care System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion